November 8, 2012

First 29 Cases Treated in US Clinical Trial of new Minimally Invasive, All-Femto Laser Vision Correction Method

One month results will be presented at a Carl Zeiss symposium at AAO 2012

DUBLIN/California/USA, JENA/Germany, 11/08/2012.
Carl Zeiss Meditec announced that the first 29 subjects in the VisuMax IDE clinical trial in the US have been treated with the ReLEx® smile procedure for the correction of spherical myopia with the VisuMax® femtosecond laser. One month results for the first 15 subjects will be presented at a Carl Zeiss Meditec symposium at the 2012 American Academy of Ophthalmology Annual Meeting in Chicago. The company received conditional approval from the US FDA to initiate the clinical trial in April 2012.

Jon Dishler, MD, the Medical Monitor for the United States VisuMax clinical trial and the first study site to initiate treatments using the ReLEx smile procedure had the following comment, “My perception is that the ReLEx smile procedure is the first significant innovation in laser vision correction since it became popular almost 20 years ago. Based on positive international experience, we are pleased to have been chosen to lead the US clinical trial of this procedure. We look forward to reporting our results, along with those of the other investigators.”

ReLEx smile is laser vision correction by small incision lenticule extraction and was developed by Carl Zeiss Meditec for refractive surgery. The pro- cedure combines femtosecond laser technology and precise lenticule extraction for minimally invasive laser vision correction for the first time – all in a single system: the VisuMax Femtosecond Laser from Carl Zeiss Meditec. While in LASIK procedures the excimer laser vaporizes tissue, the ReLEx smile method generates a refractive lenticule in the intact cornea with the femtosecond laser. The surgeon then removes the lenticule through a small, less-than-four-millimeter incision without needing to move the patient to an excimer laser. “With the first results of the clinical trial of ReLEx smile in the US, we take further steps to make this procedure available to surgeons in the US,” says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “This progress underlines the promising development in the first year after market introduction.”

ReLEx smile, which is the first small incision, single-step and all-femto vision correction method, was launched internationally in Septem-
ber 2011. It is already launched in key markets such as Europe, China and India. About 60 clinicians globally perform the procedure today and more than 12,000 eyes have been treated so far.

Contact for the press:

Alice Swinton
Corporate Communications
Carl Zeiss Meditec, Inc.
Phone: +1 925-557-4317
Email: alice .swinton @zeiss .com

Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-332
Email: pr ess @meditec .zeiss .com

Contact for investors:
Henriette Meyer
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-106
Email: inve stors @meditec .zeiss .comNumber: 044/12

Number of Words: 426
Number of Signs: 2819